Home World News Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk... World News Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 575 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and... July 1, 2020 FDA Approves Osimertinib with Platinum-Based Chemotherapy for EGFR-mutated Locally Advanced or... February 23, 2024 What could DeepMind ‘solving’ the protein folding problem mean for cancer... December 23, 2020 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for... June 7, 2019 Load more HOT NEWS After Misdiagnosis, Mom Found Out She Had Terminal Breast Cancer Shortly... At NCI, A Robust and Rapid Response to the COVID-19 Pandemic New ESMO President 2029-2030 Elected “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de...
